Transient MEK inhibitor-associated retinopathy in metastatic melanoma

Annals of Oncology

Volumn 25, Issue 7, 2014, Pages 1437-1441

  Urner Bloch, U ^a   Urner, M ^b   Stieger, P ^a   Galliker, N ^a   Winterton, N ^a   Zubel, A ^c   Moutouh de Parseval, L ^c   Dummer, Reinhard ^a   Goldinger, S M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

MEK inhibition; Melanoma; Neuroretinal detachment; Optical coherence tomography; Visual disturbance

Indexed keywords

BINIMETINIB; CHIR 265; ENCORAFENIB; LGX 818; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL FEATURE; COLOR VISION TEST; CONTROLLED STUDY; CUTANEOUS MELANOMA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EYE EXAMINATION; FEMALE; HUMAN; INCIDENCE; INDOCYANINE GREEN ANGIOGRAPHY; MALE; METASTATIC MELANOMA; MONOTHERAPY; MULTIMODAL IMAGING; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PRIORITY JOURNAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINOPATHY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; MELANOMA; METASTASIS; PATHOLOGY; RETINA DISEASE;

HUMANS; MAP KINASE KINASE KINASES; MELANOMA; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; RETINAL DISEASES;

EID: 84903700501     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu169     Document Type: Article

References (36)

1. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
2. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
3. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
4. Fremin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010; 3: 8.
5. Lorusso PM, Adjei AA, Varterasian M et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23: 5281-5293.
6. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011; 24: 879-897.
7. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
8. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
9. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
10. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
11. Ascierto PA, Schadendorf D, Berking C et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, openlabel phase 2 study. Lancet Oncol 2013; 14: 249-256.
12. Carvajal RD, Sosman JA, Quevedo F et al. Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). J Clin Oncol 2013; 31: abstr CRA9003.
13. Dummer R, Flaherty KT. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol 2012; 24: 150-154.
14. Lemech C, Infante J, Arkenau HT. Combination molecularly targeted drug therapy in metastatic melanoma: progress to date. Drugs 2013; 73: 767-777.
15. Rinderknecht JD, Goldinger SM, Rozati S et al. RASopathic skin eruptions during vemurafenib therapy. PLoS One 2013; 8: e58721.
16. Schad K, Baumann Conzett K, Zipser MC et al. Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010; 16: 1058-1064.
17. Renouf DJ, Velazquez-Martin JP, Simpson R et al. Ocular toxicity of targeted therapies. J Clin Oncol 2012; 30: 3277-3286.
18. Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol 2012; 6: 53-66.
19. Huang W, Yang AH, Matsumoto D et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther 2009; 25: 519-530.
20. Infante JR, Fecher LA, Falchook GS et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 773-781.
21. Schoenberger SD, Kim SJ. Bilateral multifocal central serous-like chorioretinopathy due to MEK inhibition for metastatic cutaneous melanoma. Case Rep Ophthalmol Med 2013; 2013: 673796.
22. Wang M, Munch IC, Hasler PW et al. Central serous chorioretinopathy. Acta Ophthalmol 2008; 86: 126-145.
23. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996; 121: 26-34.
24. Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol 2011; 21(Suppl 6): S3-S9.
25. Zografos L, Ducrey N, Beati D et al. Metastatic melanoma in the eye and orbit. Ophthalmology 2003; 110: 2245-2256.
26. Read RW, Zamir E, Rao NA. Neoplastic masquerade syndromes. Surv Ophthalmol 2002; 47: 81-124.
27. Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001; 21: 173-187.
28. Kuznetcova TI, Cech P, Herbort CP. The mystery of angiographically silent macular oedema due to taxanes. Int Ophthalmol 2012; 32: 299-304.
29. Johnson MW. Etiology and treatment of macular edema. Am J Ophthalmol 2009; 147: 11-21.e11.
30. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010; 55: 108-133.
31. Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol 1988; 106: 1190-1195.
32. Wolfensberger TJ. The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol 1999; 97: 387-397.
33. Pikkel J, Beiran I, Ophir A et al. Acetazolamide for central serous retinopathy. Ophthalmology 2002; 109: 1723-1725.
34. Georgakopoulos CD, Makri OE, Vasilakis P et al. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clin Exp Optom 2012; 95: 233-236.
35. Ehlers JP, Rayess H, Steinle N. Topical dorzolamide therapy for taxane-related macular oedema. Eye (Lond) 2013; 27: 102-104.
36. Salvatore S, Fishman GA, Genead MA. Treatment of cystic macular lesions in hereditary retinal dystrophies. Surv Ophthalmol 2013; 58: 560-584.